CD274 and neoplasm: To improve response rates, different combinations with anti-PD1-/PD-L1, including chemotherapy to release tumor antigens, antiangiogenic drugs to accelerate T-cell movement into the tumor, and improved lymph node effector T-cell priming and activation by anti-CTLA-4, DNA damage agents such as poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) or vaccines to enhance T-cell reactivity against neoantigens, have been used (Figure 4) (64).